Get the Stockscreener App
0.62
8.89%
0.0506
After Hours:
.60
-0.02
-3.23%
BiomX Inc stock is traded at $0.62, with a volume of 96,757.
It is up +8.89% in the last 24 hours and up +21.81% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.5694
Open:
$0.5666
24h Volume:
96,757
Relative Volume:
1.17
Market Cap:
$11.27M
Revenue:
-
Net Income/Loss:
$-26.56M
P/E Ratio:
-0.8267
EPS:
-0.75
Net Cash Flow:
$-22.29M
1W Performance:
-2.21%
1M Performance:
+21.81%
6M Performance:
-81.29%
1Y Performance:
-77.69%
1-Day Range:
$0.5666
$0.6299
1-Week Range:
$0.56
$0.69
52-Week Range:
$0.48
$8.55
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.62 | 11.27M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
BitMart Research: BMX 2024 Annual Report - GlobeNewswire Inc.
BiomX Inc. Regains Compliance with NYSE American Listing Standards - Defense World
BiomX regains NYSE compliance - Investing.com
BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards - The Manila Times
BiomX Regains NYSE American Listing Compliance After Meeting All Standards - StockTitan
BiomX (NYSEAMERICAN:PHGE) Stock Price Down 12.2% – Should You Sell? - Defense World
BiomX (PHGE) 5-Day RSI : 13.43 (As of Nov. 20, 2024) - GuruFocus.com
BiomX Announces Third Quarter 2024 Financial Results and Clinical Program Updates - Defense World
Biomx stock plunges to 52-week low, hits $0.61 - Investing.com India
Biomx stock plunges to 52-week low, hits $0.61 By Investing.com - Investing.com Canada
BiomX shares hold Buy rating from H.C. Wainwright on Q3 results - Investing.com Canada
BiomX Inc. (AMEX:PHGE) Q3 2024 Earnings Call Transcript - Insider Monkey
BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net In - GuruFocus.com
BiomX Inc. Reports Q3 2024 Financial Turnaround - TipRanks
BiomX Inc (PHGE) Quarterly 10-Q Report - Quartzy
BiomX Inc (PHGE) Reports Q3 2024 Net Income of $9.6 Million Amid Increased R&D and Administrative Expenses - GuruFocus.com
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates - The Manila Times
BiomX Completes Trial Enrollment, Reports $9.6M Net Income in Q3 Despite Program Delays | PHGE Stock News - StockTitan
BiomX (NYSEMKT:PHGE) Trading 4.6% Higher – Time to Buy? - Defense World
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024 - GlobeNewswire
Biomx stock plunges to 52-week low of $0.72 amid market challenges By Investing.com - Investing.com South Africa
Biomx stock plunges to 52-week low of $0.72 amid market challenges - Investing.com India
Biomx stock plunges to 52-week low, hits $0.87 - Investing.com India
Biomx stock plunges to 52-week low, hits $0.87 By Investing.com - Investing.com South Africa
BiomX (NYSEMKT:PHGE) Trading Down 2.3%Here's Why - MarketBeat
BiomX announces a mandatory unit separation - MSN
BiomX announces mandatory unit separation - Yahoo Finance
BiomX Announces a Mandatory Unit Separation - The Manila Times
BiomX Inc (PHGE) Q2 2024 Earnings Call Highlights: Strong Financial Turnaround and Promising ... - Yahoo Finance
BiomX (NYSEAMERICAN:PHGE) Shares Down 1.5% – What’s Next? - Defense World
Biomx stock plunges to 52-week low, hitting $0.92 - Investing.com
Biomx stock plunges to 52-week low, hitting $0.92 By Investing.com - Investing.com South Africa
BiomX (NYSEMKT:PHGE) Stock Price Down 1% - Defense World
BiomX Shares Phage Therapy Advances and Vision - TipRanks
Bacteriophages Therapy Market Size, Share And Growth Analysis - openPR
BiomX Stock Gains From Favorable Study Data Presentation on BX004 - Yahoo Finance
BiomX to present data from Phase 1b/2a study of BX004 - TipRanks
BiomX to Provide Latest Update on Positive Phase 1b/2a - GlobeNewswire
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference - StockTitan
Biomx stock plunges to 52-week low, hits $1.05 - Investing.com
BiomX (NYSEMKT:PHGE) Trading Down 5.4% - MarketBeat
BiomX (NYSEMKT:PHGE) Shares Down 5.4% - Defense World
Bacteriophage Therapy Market Projected To Witness Substantial Growth, 2024-2031: Enbiotix, Inc., Nextbiotics, - EIN News
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
PHGEBiomX Inc. Latest Stock News & Market Updates - StockTitan
Biomx stock plunges to 52-week low at $1.15 amid market challenges - Investing.com
BiomX to Present Positive Phase 1b/2a Clinical Trial Data - GlobeNewswire
BiomX to present cinical trial data for BX004 at ERS - TipRanks
BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024 - StockTitan
Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Drops By 92.9% - MarketBeat
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):